Jenny Erica Beckman, Niubel Díaz Padilla, Afke van der Woud, Peter van den Burg, Vĕra Novotny
{"title":"Perceptions of deferred blood donors regarding false-positive screening results for infectious diseases and European blood establishment strategies.","authors":"Jenny Erica Beckman, Niubel Díaz Padilla, Afke van der Woud, Peter van den Burg, Vĕra Novotny","doi":"10.1111/vox.70115","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>This study explores the perceptions of deferred blood donors in the Netherlands regarding the information provided upon receiving false-positive screening (FPS) deferral letters for infectious diseases. To ensure blood supply safety, rigorous screening for infectious agents is implemented by blood establishments. However, FPS results can create challenges after donor notification, leading to psychological distress.</p><p><strong>Materials and methods: </strong>The study purposively selected whole-blood donors who had received deferral letters due to two FPS results between April and October 2023. Semi-structured interviews, guided by the Health Belief Model (HBM), examined health behaviours through seven constructs. Additionally, a survey of European Blood Alliance (EBA) members was conducted to gather insights on FPS management practices. Interview transcripts were coded and modelled to illustrate relationships between the themes.</p><p><strong>Results: </strong>Ten in-depth interviews were held, revealing varied responses: some donors felt reassured by safety protocols, while the majority experienced psychological distress. Key themes included emotional reactions, contact methods, follow-up communication, engagement with Sanquin Blood Supply and altruistic motivations. The EBA survey shows varied FPS notification practices, rejection protocols, limited donor reaction studies and diverse support measures.</p><p><strong>Conclusion: </strong>Improving communication clarity, providing follow-up procedures and adopting best practices from EBA members can enhance donor experience. These efforts are essential for refining the deferral process and improving donor perceptions, ultimately benefiting the donor and the blood supply system.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70115","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: This study explores the perceptions of deferred blood donors in the Netherlands regarding the information provided upon receiving false-positive screening (FPS) deferral letters for infectious diseases. To ensure blood supply safety, rigorous screening for infectious agents is implemented by blood establishments. However, FPS results can create challenges after donor notification, leading to psychological distress.
Materials and methods: The study purposively selected whole-blood donors who had received deferral letters due to two FPS results between April and October 2023. Semi-structured interviews, guided by the Health Belief Model (HBM), examined health behaviours through seven constructs. Additionally, a survey of European Blood Alliance (EBA) members was conducted to gather insights on FPS management practices. Interview transcripts were coded and modelled to illustrate relationships between the themes.
Results: Ten in-depth interviews were held, revealing varied responses: some donors felt reassured by safety protocols, while the majority experienced psychological distress. Key themes included emotional reactions, contact methods, follow-up communication, engagement with Sanquin Blood Supply and altruistic motivations. The EBA survey shows varied FPS notification practices, rejection protocols, limited donor reaction studies and diverse support measures.
Conclusion: Improving communication clarity, providing follow-up procedures and adopting best practices from EBA members can enhance donor experience. These efforts are essential for refining the deferral process and improving donor perceptions, ultimately benefiting the donor and the blood supply system.
期刊介绍:
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.